6.
Anderson-Crannage M, Ascension A, Ibanez-Sole O, Zhu H, Schaefer E, Ottomanelli D
. Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin. Front Immunol. 2023; 14:1211505.
PMC: 10557493.
DOI: 10.3389/fimmu.2023.1211505.
View
7.
Gurevich I, Agarwal P, Zhang P, Dolorito J, Oliver S, Liu H
. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022; 28(4):780-788.
PMC: 9018416.
DOI: 10.1038/s41591-022-01737-y.
View
8.
Maseda R, Martinez-Santamaria L, Sacedon R, Butta N, Arriba M, Garcia-Barcenilla S
. Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. Front Med (Lausanne). 2020; 7:576558.
PMC: 7726418.
DOI: 10.3389/fmed.2020.576558.
View
9.
Pangrazzi L, Reidla J, Arana J, Naismith E, Miggitsch C, Meryk A
. CD28 and CD57 define four populations with distinct phenotypic properties within human CD8 T cells. Eur J Immunol. 2019; 50(3):363-379.
PMC: 7079235.
DOI: 10.1002/eji.201948362.
View
10.
Bechara R, McGeachy M, Gaffen S
. The metabolism-modulating activity of IL-17 signaling in health and disease. J Exp Med. 2021; 218(5).
PMC: 8025242.
DOI: 10.1084/jem.20202191.
View
11.
Judge S, Murphy W, Canter R
. Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. Front Cell Infect Microbiol. 2020; 10:49.
PMC: 7031155.
DOI: 10.3389/fcimb.2020.00049.
View
12.
Zhang C, Wang X, Li S, Twelkmeyer T, Wang W, Zhang S
. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun. 2019; 10(1):1507.
PMC: 6447531.
DOI: 10.1038/s41467-019-09212-y.
View
13.
Santucci C, Alexandru M, Chen X, Mellerio J, Karagiannis S, Jackow-Malinowska J
. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Hum Immunol. 2024; 85(3):110805.
DOI: 10.1016/j.humimm.2024.110805.
View
14.
Mulder P, Vlig M, Boekema B, Stoop M, Pijpe A, van Zuijlen P
. Persistent Systemic Inflammation in Patients With Severe Burn Injury Is Accompanied by Influx of Immature Neutrophils and Shifts in T Cell Subsets and Cytokine Profiles. Front Immunol. 2021; 11:621222.
PMC: 7879574.
DOI: 10.3389/fimmu.2020.621222.
View
15.
Lanuza P, Pesini C, Arias M, Calvo C, Ramirez-Labrada A, Pardo J
. Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?. Front Immunol. 2020; 10:3010.
PMC: 6962251.
DOI: 10.3389/fimmu.2019.03010.
View
16.
Reimer-Taschenbrecker A, Hess M, Davidovic M, Hwang A, Hubner S, Hofsaess M
. IL-6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study. J Eur Acad Dermatol Venereol. 2024; 39(1):202-209.
PMC: 11664450.
DOI: 10.1111/jdv.19898.
View
17.
Chiurchiu V, Leuti A, Maccarrone M
. Bioactive Lipids and Chronic Inflammation: Managing the Fire Within. Front Immunol. 2018; 9:38.
PMC: 5797284.
DOI: 10.3389/fimmu.2018.00038.
View
18.
Rogers C, Gibson M, Kern J, Martin L, Robertson S, Daniel B
. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). JAAD Int. 2021; 2:134-152.
PMC: 8362226.
DOI: 10.1016/j.jdin.2020.12.007.
View
19.
Giesen C, Wang H, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B
. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014; 11(4):417-22.
DOI: 10.1038/nmeth.2869.
View
20.
Ebens C
. Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa. EMBO Mol Med. 2021; 13(10):e14864.
PMC: 8495457.
DOI: 10.15252/emmm.202114864.
View